Pulmonary Arterial Hypertension: Stepped, Novel, and Multidisciplinary Approaches to Management
This activity is supported by educational grants from Merck & Co., Inc. and United Therapeutics, a public benefit company.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by educational grants from Merck & Co., Inc. and United Therapeutics, a public benefit company.
Activity Description
Because untreated pulmonary arterial hypertension (PAH) can lead to right heart failure and death, early diagnosis and treatment are critical. However, diagnosis can be challenging due to the heterogeneous presentation of pulmonary hypertension, delaying timely referral to specialty centers for workup, risk assessment, and treatment. Despite multiple available FDA-approved therapies, many patients do not achieve low-risk status on treatment, worsening their prognosis. To provide optimal patient care, clinicians involved in PAH management should be aware of recent developments, including updated practice guidelines and promising emerging therapies. In this educational activity, experts will review recommended diagnostic strategies, approaches to risk assessment, and evidence-based treatment. Faculty will also examine the latest clinical evidence for emerging agents and discuss strategies for multidisciplinary and interprofessional management to improve quality of life and outcomes of patients with PAH.
Target Audience
The intended audience for this activity is pulmonologists, cardiologists, advanced practice providers, and other health care professionals involved in the management of patients with pulmonary arterial hypertension.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review revised guidelines pertaining to the use of stepped approaches and algorithms in the diagnosis and treatment of patients with pulmonary arterial hypertension (PAH).
- Differentiate novel advances in the treatment of PAH in terms of mechanism of action, safety, and efficacy.
- Summarize the need for multidisciplinary and interprofessional care teams to improve the overall management and outcomes for patients with PAH.
Activity Chair
Mardi Gomberg-Maitland, MD, MSc, FACC, FAHA, FCCP
Professor of Medicine, Division of Cardiology
Walter G. Ross Professor of Clinical Research
Chief Clinical Research Officer, OCR
GWU School of Medicine and Health Sciences
Director of Pulmonary Hypertension
Washington, DC
Faculty
Charles D. Burger, MD, FCCP, ATSF
Professor of Medicine, Division of Pulmonary Medicine, Department of Internal Medicine
Mayo Clinic School of Medicine
Jacksonville, FL
Fernando Torres, MD
Professor of Medicine
Clinical Chief, Division of Pulmonary and Critical Care Medicine
UT Southwestern Medical Center
Dallas, TX
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 29, 2024. PAs should only claim credit commensurate with the extent of their participation.
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.3 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23106437. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This enduring material is approved for 1 year from the date of original release, November 30, 2023, to November 29, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate, AAPA Category 1 CME credit certificate, or Contact Hour certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Charles D. Burger, MD, FCCP, ATSF
No relevant financial relationships to disclose.
Mardi Gomberg-Maitland, MD, MSc, FACC, FAHA, FCCP
Consultant: Aerami, Acceleron/Merck, Bayer, Janssen, Keros, United Therapeutics
Scientific Advisory Board: United Therapeutics
Fernando Torres, MD
Independent Research Contractor: Bellerophon
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this lecture is available upon request. Requests should include the activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com